Global Osteosarcoma Market Growth (Status and Outlook) 2023-2029

Global Osteosarcoma Market Growth (Status and Outlook) 2023-2029

An osteosarcoma (OS) is a cancerous tumor in a bone. Specifically, it is an aggressive malignant neoplasm that arises from primitive transformed cells of mesenchymal origin (and thus a sarcoma) and that exhibits osteoblastic differentiation and produces malignant osteoid. Osteosarcoma is the most common histological form of primary bone cancer. It is most prevalent in teenagers and young adults.

LPI (LP Information)' newest research report, the “Osteosarcoma Industry Forecast” looks at past sales and reviews total world Osteosarcoma sales in 2022, providing a comprehensive analysis by region and market sector of projected Osteosarcoma sales for 2023 through 2029. With Osteosarcoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Osteosarcoma industry.

This Insight Report provides a comprehensive analysis of the global Osteosarcoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Osteosarcoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Osteosarcoma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Osteosarcoma and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Osteosarcoma.

The global Osteosarcoma market size is projected to grow from US$ 506.9 million in 2022 to US$ 650.6 million in 2029; it is expected to grow at a CAGR of 3.6% from 2023 to 2029.

Osteosarcoma is the eighth-most common form of childhood cancer, comprising 2.4% of all malignancies in pediatric patients, and about 20% of all primary bone cancers. Incidence rates for osteosarcoma in U.S. patients under 20 years of age are estimated at 5.0 per million per year in the general population, with a slight variation between individuals of black, Hispanic, and white ethnicities (6.8, 6.5, and 4.6 per million per year, respectively). It is slightly more common in males (5.4 per million per year) than in females (4.0 per million per year).

This report presents a comprehensive overview, market shares, and growth opportunities of Osteosarcoma market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Intramedullary Osteosarcoma
Juxtacortical Osteosarcoma
Extraskeletal Osteosarcoma

Segmentation by application
Hospital
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Spectrum Pharmaceuticals
Hikma Pharmaceuticals
Baxter
Isofol
Advaxis
Bellicum Pharmaceuticals
Novartis

Please note: The report will take approximately 2 business days to prepare and deliver.